Home Opthea Limited

Opthea Limited

Final Patient Visit in Phase 2b Wet AMD Clinical Trial Completed

Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, announced today that the final patient in the Company’s Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD) has completed their last clinical visit.